Quarterly ResultMay 12, 2026, 04:11 PM
Solid Biosciences Doses First Patient in Phase 3 Duchenne Trial; Q1 Net Loss $56.7M
AI Summary
Solid Biosciences Inc. reported its first-quarter 2026 financial results and provided a comprehensive business update, highlighting significant progress across its pipeline. The company dosed the first participant in the Phase 3 IMPACT DUCHENNE clinical trial for SGT-003 and secured key European regulatory designations, including Orphan drug status and a positive EMA opinion on its Pediatric Investigation Plan. Financially, Solid Biosciences ended Q1 2026 with $380.7 million in cash, cash equivalents, and available-for-sale securities, extending its cash runway into H1 2028, despite reporting a net loss of $56.7 million for the quarter.
Key Highlights
- Solid Biosciences dosed the first participant in the Phase 3 IMPACT DUCHENNE clinical trial for SGT-003.
- SGT-003 received a positive opinion on its Pediatric Investigation Plan from the EMA and Orphan drug designation from the European Commission.
- 47 participants have been dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial for SGT-003, showing a consistent safety profile.
- The second participant was dosed in the Phase 1b FALCON clinical trial for SGT-212 (Friedreich's Ataxia), with no serious adverse events.
- Solid Biosciences anticipates dosing the first participant in the Phase 1b ARTEMIS clinical trial for SGT-501 (CPVT) in H2 2026.
- Cash, cash equivalents, and available-for-sale securities totaled $380.7 million as of March 31, 2026.
- The company's cash runway is anticipated to extend into H1 2028.
- Net loss for Q1 2026 was $56.7 million, compared to $39.3 million in Q1 2025.
- Research and Development expenses increased to $46.1 million in Q1 2026 from $30.9 million in Q1 2025.